SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA issues Warning Letter to Wockhardt’s step down subsidiary

23 Nov 2016 Evaluate

Wockhardt’s step down subsidiary - CP Pharmaceuticals, Wrexham, United Kingdom, has been issued a Warning Letter by the US Food and Drug Administration (USFDA). Currently, there is no business being conducted from CP Pharmaceuticals to the US Market.

The company has already initiated required steps to address the concerns raised by USFDA and will be responding to the Agency within the prescribed time.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.



Wockhardt Share Price

1393.05 -3.75 (-0.27%)
20-Apr-2026 11:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.10
Dr. Reddys Lab 1238.25
Cipla 1238.70
Zydus Lifesciences 941.50
Lupin 2327.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×